Cargando…

A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody

PURPOSE: To review pharmacokinetic and pharmacodynamic characteristics of antibodies that bind to soluble ligands within the framework of calcitonin gene-related peptide antibodies. OVERVIEW: Calcitonin gene-related peptide has been implicated in the pathophysiology of migraine. Galcanezumab is an a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kielbasa, William, Helton, Danielle L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710614/ https://www.ncbi.nlm.nih.gov/pubmed/30917684 http://dx.doi.org/10.1177/0333102419840780

Ejemplares similares

Population Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine
por: Kielbasa, William, et al.
Publicado: (2019)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
por: Monteith, David, et al.
Publicado: (2017)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
por: Szkutnik-Fiedler, Danuta
Publicado: (2020)

Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021)

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
por: Kubota, Gabriel Taricani
Publicado: (2022)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
por: Sevivas, Hugo, et al.
Publicado: (2022)

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
por: Argyriou, Andreas A., et al.
Publicado: (2022)

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
por: Martelletti, Paolo
Publicado: (2020)

Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine
por: Lovato, Andrea, et al.
Publicado: (2023)

Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review
por: Aditya, Suruchi, et al.
Publicado: (2023)

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
por: Han, Lin, et al.
Publicado: (2019)

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
por: Vandervorst, Fenne, et al.
Publicado: (2021)

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
por: Simioni, Caio Vinicius de Meira Grava
Publicado: (2022)

Galcanezumab for migraine
Publicado: (2020)

Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review
por: Albanese, Maria, et al.
Publicado: (2022)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
por: Ailani, Jessica, et al.
Publicado: (2021)

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
por: Caronna, E., et al.
Publicado: (2021)

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
por: Caronna, E., et al.
Publicado: (2021)

Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
por: Charleston, Larry, et al.
Publicado: (2023)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
por: Caronna, Edoardo, et al.
Publicado: (2021)

Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
por: Iannone, Luigi Francesco, et al.
Publicado: (2022)

Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies: A Prospective Follow-up Study
por: de Vries Lentsch, Simone, et al.
Publicado: (2022)

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
por: Barbanti, Piero, et al.
Publicado: (2022)

Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review
por: Muddam, Meghana Reddy, et al.
Publicado: (2023)

CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab
por: De Luca, Ciro, et al.
Publicado: (2021)

Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis
por: Rodríguez-Fernández, Karine, et al.
Publicado: (2022)

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy
por: Mullin, Kathleen, et al.
Publicado: (2020)

Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
por: Cohen, Fred, et al.
Publicado: (2022)

Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
por: Haanes, Kristian Agmund, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections
por: Wang-Lin, Shun Xin, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
por: Chakraborty, Abhijit, et al.
Publicado: (2012)

Pharmacokinetics and pharmacodynamics of mepolizumab, an anti–interleukin 5 monoclonal antibody, in healthy Japanese male subjects
por: Tsukamoto, Naohiro, et al.
Publicado: (2015)

Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor
por: Blumenfeld, Andrew, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p5thrlo917e9triqg49qmufq42